First Human Trial Tests Epigenetic Reprogramming Therapy for Glaucoma

In June 2026, the inaugural participant in a Phase 1 clinical trial received an experimental epigenetic reprogramming therapy targeting glaucoma and other optic neuropathies. The approach, which uses a set of transcription factors to reset cellular aging markers, previously restored youthful characteristics to retinal ganglion cells and improved visual function in mouse models.

Researchers say the eye offers a practical testing ground because it can be accessed locally and visual outcomes can be measured precisely. “The eye is close to an ideal organ for this kind of work,” said Steve Horvath, a professor of medicine at UCLA, noting its anatomical self-containment and the ability to deliver a local dose.

Jeffrey Goldberg, chair of ophthalmology at Stanford University, highlighted that earlier work on Kruppel-like factors demonstrated the potential for gene-based regeneration of damaged optic nerves. He added that newer transcription-factor combinations could further enhance the plasticity of adult neurons.

The trial will not determine efficacy, which will require larger studies, but it represents the first human application of cellular rejuvenation for vision loss. Experts caution that safety remains the primary concern, emphasizing the need to avoid unintended changes such as loss of cell identity or abnormal growth. Matt Kaeberlein, a biogerontologist at the University of Washington, noted that the therapy is likely to benefit eyes where cells are still present but functionally impaired, rather than cases with extensive cell death.

If successful, the technology could complement existing treatments that focus on slowing disease progression, potentially offering partial restoration of sight for conditions like glaucoma, age-related macular degeneration, and optic neuritis. The broader implications extend to other neurodegenerative diseases, as the eye provides a model for localized delivery without systemic exposure.